Summary of clinical and molecular results of the 18 adenocarcinoma samples
| Case no. | Sex | Age (years) | Tumour site | Biopsy/surgical sample | %ct | EGFR mutation status (NGS) | KRAS mutation status (NGS) | Other oncogenic alterations | Idylla EGFR mutation assay | Idylla KRAS mutation test | EGFRT790M ddPCR with mutant fraction |
|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | F | 54 | Lung | B | 40 | c.2156G>C(p.G719A) and c.2303G>T(p.S768I) | – | – | G719X and S768I | – | T790M+ (0,36%) |
| #2 | F | 57 | Lung | B | 60 | c.2240_2257del(p.L747_P753delinsS) | – | – | DEL EXON 19 | – | T790M− |
| #3 | F | 61 | Lung | B | 50 | c.2573T>G (p.L858R) | – | – | L858R | – | T790M− |
| #4 | M | 66 | Peritoneum | B | 20 | c.2235_2249del (p.E746_A750del) and c.2369C>T (p.T790M) | – | – | DEL EXON 19 | – | T790M+ (4.6%) |
| #5 | F | 49 | Lung | S | 30 | c.2236_2250del(p.E746_A750del) | – | – | DEL EXON 19 | – | T790M+ (1.17%) |
| #6 | M | 78 | Lung | S | 60 | c.2573T>G(p.L858R) | – | – | L858R | – | T790M− |
| #7 | F | 61 | Lung | B | 50 | c.2235_2249del(p.K745_A750delinsK) and c.2369C>T (p.T790M) | – | – | DEL EXON 19 | – | T790M+ (4,1%) |
| #8 | F | 86 | Lung | B | 30 | c.2573T>G (p.L858R) and c.2369C>T (p.T790M) | – | – | L858R | – | T790M+ (1.2%) |
| #9 | F | 58 | Lung | S | 60 | c.2156G>C(p.G719A) and c.2582T>A (p.L861Q) | – | – | G719X and L861Q | – | T790M+ (0.2%) |
| #10 | F | 72 | Lung | S | 80 | c.2573T>G (p.L858R) and c.2369C>T (p.T790M) | – | – | L858R and T790 M | – | T790M+ (51.6%) |
| #11 | F | 61 | Lymph node | B | 40 | – | c.183A>T (p.Q61H) | – | – | Q61H | T790M+ (0.19%) |
| #12 | F | 70 | Lung | S | 80 | – | c.34G>T (p.G12C) | – | – | G12C | T790M+ (0.13%) |
| #13 | F | 63 | Lung | S | 60 | – | c.38G>A (p.G13D) | – | – | G13D | T790M+ (0.17%) |
| #14 | F | 69 | Lung | S | 70 | – | c.35G>C (p.G12A) | – | – | G12A | T790M+ (0.18%) |
| #15 | M | 85 | Lung | S | 40 | – | – | BRAF c.1799T>A (p.V600E) | – | – | T790M+ (0.23%) |
| #16 | M | 35 | Pleura | S | 70 | – | – | ALK rearrangement | – | – | T790M+ (0.22%) |
| #17 | M | 68 | Liver | B | 80 | – | – | ROS1 rearrangement | – | – | T790M− |
| #18 | F | 47 | Lymph node | S | 80 | – | – | RET rearrangement | – | – | T790M+ (0.17%) |
%ct, percentage of tumour cells; –, no genetic alteration detected; B, biopsy; ddPCR, droplet digital PCR; F, female; M, male; NGS, next-generation sequencing; S, surgical sample.